SAPIEN 3球囊扩张瓣膜TAVI术后1年结局:SOURCE 3注册研究
SOURCE 3为欧洲多中心批准后注册研究,前瞻性纳入1946例接受最新一代球囊扩张SAPIEN 3瓣膜TAVI的患者,平均年龄81.6岁。1年全因死亡12.6%、心血管死亡8.0%、卒中3.1%,新起搏器13.2%;中重度瓣周漏罕见(2.6%),且不再影响结局。
要点
- SAPIEN 3 TAVI术后1年全因死亡12.6%,心血管死亡8.0%。
- 1年卒中3.1%、致残性卒中1.4%、新起搏器13.2%。
- 中度瓣周漏仅2.6%,重度为零,瓣周漏不再影响结局。
核心结论
- SOURCE 3注册研究中SAPIEN 3 TAVI术后1年并发症率和死亡率均较低。
- 因高度瓣周漏发生率低,该变量不再影响结局。
研究设计与样本
- 欧洲10国80中心的前瞻性批准后多中心注册研究,2014年7月至2015年10月连续纳入1946例患者。
- 患者平均年龄81.6±6.7岁,男性占52%,全部终点按VARC-2定义由独立委员会裁决。
主要发现
- 1年全因死亡12.6%,心血管死亡8.0%,卒中3.1%,致残性卒中1.4%,新起搏器13.2%。
- 死亡原因中62.0%为心血管性、38.0%为非心血管性,心力衰竭(13.4%)和肺部并发症(12.7%)为主要致死原因。
- 多变量分析显示NYHA IV级和肾功能不全是死亡预测因素,较高BMI改善生存。
- 1年时中度瓣周漏2.6%,重度(零)瓣周漏罕见。
临床怎么用
- SAPIEN 3用于中高危老年主动脉瓣狭窄患者TAVI,1年结局支持其安全性。
- 关注NYHA IV级和肾功能不全患者的术后死亡风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Transcatheter aortic valve implantation (TAVI) has developed from a procedure for patients with aortic stenosis inoperable or high risk for surgery, into a treatment option even for intermediate risk elderly patients. This development has been facilitated by the clinical learning curve and constant improvements of transcatheter heart valves used. We present total 1-year results of SOURCE 3, the European post-approval multicentre registry of the latest generation balloon expandable SAPIEN 3TM (Edwards Lifesciences, Irvine, CA, USA). METHODS AND RESULTS: Participating centres have submitted their consecutive experience with the SAPIEN 3, dependent on patients consent. Data were prospectively collected and all end point-related outcomes adjudicated according to VARC-2 definitions by an independent committee. Between July 2014 and October 2015, in total 1946 patients (mean age 81.6 ± 6.7 years, 52% male) were enrolled in 80 centres from 10 European countries. At 1 year, all-cause mortality was 12.6%, cardiovascular mortality 8.0%, stroke 3.1%, disabling stroke 1.4%, and rate of new pacemakers 13.2%. Causes of death were 62.0% cardiovascular and 38.0% non-cardiovascular, with heart failure (13.4%) and pulmonary complications (12.7%) being the main reasons for fatal outcomes. Multivariable analysis identified New York Heart Association Class IV and renal insufficiency as predictors of mortality, while higher BMI's improved survival. Severe (zero) and moderate paravalvular leakage (2.6%) was rare at 1 year. CONCLUSION: In SOURCE 3, we observe a low complication rate and mortality at 1 year. Given the low incidence of higher degree paravalvular leakages, this variable did no longer affect outcome. Clinicaltrial.gov number: NCT02698956.
引用
- Wendler O, Schymik G, Treede H, et al. SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve. Eur Heart J. 2017. PMID: 28605423. doi:10.1093/eurheartj/ehx294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。